Merck KGAA Taps PDS For Cancer Vaccine Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
The German pharma signs a deal with Indiana-based PDS Biotechnology that will use the company’s adjuvant technology to boost its own compounds.